♦ Publications

Full Length Articles, Review Articles, and Chapters

• Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin MD. Antiphospholipid Syndrome Clinical Research Task Force Report. Lupus 2011;20:219-224.

• Erkan D, Lockshin MD, on behalf of APS ACTION. APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus 2012; 21:695-698

• Levy R, Jesus GR. “APS ACTION no Brasil”. Brazilian Journal of Rheumatology 2012;52:811-814.

• Erkan D, Pierangeli S, Lockshin MD. “Task Force Report on Antiphospholipid Syndrome Clinical Research.” In: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. Eds: Erkan, Pierangeli. Springer, 2012; 247-257.

• Andreoli L, Banzato A, Chighizola, CB, Pons-Estel GJ, Ramires de Jesus G, and Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infraction, and Deep Vein Thrombosis. Arthritis Care Res (Hoboken) 2013;65:1869-1873.

• Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, Bertolaccini ML on Behalf of APS ACTION. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015;74:2028-2033.

• Chighizola C, Andreoli L, de Jesus GR, Banzato A, Pons-Estel G, Erkan D on Behalf of APS ACTION. The Association Between Antiphospholipid Antibodies and Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis. Lupus 2015;24:980-984.

• Barbhaiya M, Andrade D, Erkan D; APS ACTION. AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. Curr Rheumatol Rep. 2016;18:64

• Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT on Behalf of APS ACTION. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1:2320-2324.

• Barbhaiya M, Andrade D. Bertolaccini ML, Erkan D. AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). In: Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights. Eds: Erkan D, Lockshin MD. Springer, 2017, p: 267.

• Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, Gonzalez E, Knight JS, Uthman I, Willis R, Zhang Z, Wahl D, Zuily S, Tektonidou MG on Behalf of APS ACTION. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27:399-406.

• Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG on Behalf of APS ACTION. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody Positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository. Arthritis Care Res (Hoboken);2019:71(1);134-141.

• de Jesús GR, Sciascia S, Andrade D, Nascimento IS, Rosa R, Barbhaiya M, Tektonidou M, Banzato A, Pengo V, Ji L, Meroni PL, Ugarte A, Cohen H, Branch DW, Andreoli L, Belmont HM, Fortin PR, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Erkan D, Levy RA on Behalf of APS ACTION. Factors Associated with First Thrombosis in Patients Presenting with Obstetric Antiphospholipid Syndrome in APS Alliance For Clinical Trials & International Networking (APS ACTION) Clinical Database And Repository: a retrospective study. BJOG 2019;126(5);656-661.

• Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum. 2019 Dec;49(3):464-468.

• Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, Ugarte A, Chighizola C, Branch DW, Levy RA, Nalli C, Fortin PR, Petri M, Rodriguez E, Rodriguez-Pinto I, Atsumi T, Nascimento I, Rosa R, Banzato A, Erkan D, Cohen H, Efthymiou M, Mackie I, Bertolaccini ML; APS ACTION. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Thromb Res. 2019 Mar;175:32-36.

• Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, Sciascia S, Krillis S, Bison E, Borges Galhardo Vendramini M, Romay-Penabad Z, Qi M, Tektonidou M, Ugarte A, Chighizola C, Belmont HM, Aguirre MA, Ji L, Branch DW, de Jesus G, Fortin PR, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Sevim E, Bertolaccini ML, Pengo V, Cohen H; APS ACTION. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. J Thromb Haemost. 2019 Dec;17(12):2069-2080. PMID: 31364274

• Zuily S, Clerc-Urmès I, Bauman C, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Michael Belmont H, Zamorano MAA, Fortin P, Ji L, Efthymiou M, Cohen H, Branch DW, Jesus GR, Nalli C, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Bertolaccini ML, Vega J, Wahl D, Erkan D; APS ACTION Investigators. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus. 2020 Jul 23:961203320940776. doi: 10.1177/0961203320940776. Epub ahead of print. PMID: 32703117.

• Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Aguirre Zamorano MA, Fortin PR, Ji L, Efthymiou M, Cohen H, Branch DW, de Jesus GR, Andreoli L, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Roubey R, Bertolaccini ML, Erkan D, Barbhaiya M; APS ACTION Investigators. Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Arthritis Care Res (Hoboken). 2020 Sep 28. Epub ahead of print. PMID: 32986935.

• Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, Tektonidou MG, Ugarte A, Chighizola CB, Belmont HM, Lopez-Pedrera C, Ji L, Fortin P, Efthymiou M, de Jesus GR, Branch DW, Nalli C, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Bertolaccini ML, Cohen H, Rand J, Erkan D; APS ACTION+. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. J Rheumatol. 2021 Apr;48(4):541-547. PMID: 33259328.

• Erkan D, Sciascia S, Bertolaccini ML, Cohen H; APS ACTION Executive Committee. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Curr Rheumatol Rep. 2021 May 1;23(6):45. PMID: 33932165.

• de Azevedo Lopes E, Balbi GGM, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, Fortin PR, Lopez-Pedrera C, Ji L, Cohen H, de Jesús GR, Branch DW, Nalli C, Petri M, Rodriguez E, Kello N, Ríos-Garcés R, Knight JS, Atsumi T, Willis R, Bertolaccini ML, Erkan D, Andrade D; APS ACTION. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. Adv Rheumatol. 2021;61:64. PMID: 34711275.

• Wang X, Gkrouzman E, Andrade DCO, Andreoli L, Barbhaiya M, Belmont HM, Branch DW, de Jesús GR, Efthymiou M, Ríos-Garcés R, Gerosa M, El Hasbani G, Knight J, Meroni PL, Pazzola G, Petri M, Rand J, Salmon J, Tektonidou M, Tincani A, Uthman IW, Zuily S, Zuo Y, Lockshin M, Cohen H, Erkan D; APS ACTION. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus. 2021 Dec;30(14):2276-2285. doi: 10.1177/09612033211062523. Epub 2021 Dec 16. PMID: 34915764.

• Erton ZB, Sevim E, de Jesús GR, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, Fortin PR, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou MG, Aguirre-Zamorano MA, Branch DW, Erkan D; APS ACTION. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’). Lupus Sci Med. 2022 Jun;9(1):e000633. PMID: 35701043.

• Erton ZB, K Leaf R, de Andrade D, Clarke AE, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Gerosa M, Fortin PR, Lopez-Pedrera C, Atsumi T, Zhang Z, Cohen H, Ramires de Jesús G, Branch DW, Wahl D, Andreoli L, Rodriguez-Almaraz E, Petri M, Barilaro G, Zuo Y, Artim-Esen B, Willis R, Quintana R, Vendramini MB, Barber MW, Bertolaccini ML, Roubey R, Erkan D. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Lupus 2022;31:1770-1776. PMID: 36206383.

• Chighizola CB, Pregnolato F, Andrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, Belmont HM, Gerosa M, Fortin P, Branch DW, Andreoli L, Petri MA, Cervera R, Knight JS, Willis R, Efthymiou M, Cohen H, Erkan D, Bertolaccini ML; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). Fluctuation of Anti-Domain 1 and Anti-β₂ -Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies. Arthritis Rheumatol. 2023;75:984-995. PMID: 36704930.

• Zuo Y, Navaz S, Tsodikov A, Kmetova K, Kluge L, Ambati A, Hoy CK, Yalavarthi S, de Andrade D, Tektonidou MG, Sciascia S, Pengo V, Ruiz-Irastorza G, Belmont HM, Gerosa M, Fortin PR, de Jesus GR, Branch DW, Andreoli L, Rodriguez-Almaraz E, Petri M, Cervera R, Willis R, Karp DR, Li QZ, Cohen H, Bertolaccini ML, Erkan D, Knight JS; Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository. Arthritis Rheumatol. 2023;75:1407-1414. PMID: 36862141.

• Gkrouzman E, Willis R, Andrade D, Tektonidou MG, Pengo V, Ruiz-Irastorza G, Belmont HM, Fortin PR, Gerosa M, Signorelli F, Atsumi T, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri MA, Cervera R, Knight JS, Efthymiou M, Cohen H, Bertolaccini ML, Erkan D, Roubey R; APS ACTION. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study. Lab Invest. 2023;103(6):100147. PMID: 37044248.

• Balbi GGM, Ahmadzadeh Y, Tektonidou MG, Pengo V, Sciascia S, Ugarte A, Belmont HM, Lopez-Pedrera C, Fortin PR, Wahl D, Gerosa M, de Jesús GR, Ji L, Atsumi T, Efthymiou M, Branch DW, Nalli C, Almaraz ER, Petri M, Cervera R, Knight JS, Artim-Esen B, Willis R, Bertolaccini ML, Cohen H, Roubey R, Erkan D, Andrade D; AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (APS ACTION). Damage measured by damage index for antiphosphlipid syndrome in antiphospholipid antibody-positive patients included in APS ACTION Registry. Rheumatology (Oxford). 2023;63:772-779. PMID: 37307082.

Poster or Podium Presentations at Scientific Meetings

• Andreoli L, Banzato A, Chighizola CB, Pons-Estel GJ, Ramires de Jesus G, Lockshin MD, Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis. Arthritis & Rheumatism 2012;64:S1035 – (ACR 2012)

• Chighizola CB, Ramires de Jesus G, Andreoli L, Banzato A, Pons-Estel GJ, Lockshin MD, Erkan D on Behalf of APS ACTION. The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity. Arthritis & Rheumatism 2012;64:S744 – (ACR 2012)

• Chighizola C, Andreoli L, Banzato A, de Jesus G, Pons-Estel G, Erkan D on Behalf of APS ACTION. The Association Between Antiphospolipid Antibodies and Related Clinical Outcomes: A Critical Review Of The Literature. Arthritis & Rheumatism 2013;65:S1129 – (ACR 2013)

• Vega J, Erkan D on behalf of APS ACTION. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. 14th International Congress on aPL Abstract Book 2013; P1-19:77 – (14th International Congress on Antiphospholipid Antibodies 2013)

• Erkan D, Andrade D, Tektonidou M, Fortin P, Ugarte A, Banzato A, Tincani A, Meroni PL, Cervera R, Levy R on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Initial Analysis. Arthritis & Rheumatism 2014;66:S1253-1254 – (ACR 2014)

• Zuily S, Wahl D, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis for Identification of Different Clinical Phenotypes among Antiphospholipid Antibody-Positive Patients. Annals of Rheumatic Disease SAT0426 – (EULAR 2015)

• Bertolaccini ML, Willis R, Lakos G, Andrade D, Pengo V, Banzato A, Krilis S, Erkan D on behalf APS ACTION. APS ACTION Core Laboratory Validation Exercise: Comparison of Chemiluminescence immunoassay (CIA) and ELISA. Annals of Rheumatic Disease 2015: AB1071 – (EULAR 2015)

• Mackie IJ, Pengo V, Gray E, Andrade D, Krilis S, Willis R, Erkan D, Cohen H on behalf of APS ACTION. APS ACTION Core Laboratory Validation Exercise: An International Performance Assessment of Lupus Anticoagulant Tests Using Standardized Methods and Reagents. Journal of Thrombosis and Hemostasis 2015; 13(Suppl2):777 – (ISTH2015)

• Bertolaccini ML, Andrade D, Lakos G, Willis R, Pengo V, Banzato A, Cohen H, Krilis S, Erkan D on behalf of APS ACTION. APS ACTION Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA). Arthritis Rheumatol. 2015; 67 (suppl 10). #2190 – (ACR 2015)

• Ramires de Jesus G, Zuily S, Erkan D, Levy RA on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Determinants of Thrombosis in Patients Presenting with Obstetric APS [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10) #2198 – (ACR 2015)

• Zuily S, Chighizola CB, WAHL D, Meroni PL, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients [abstract]. Arthritis Rheumatol.2015; 67 (suppl 10)#2200 – (ACR 2015)

• Erkan D, Zuily S, Banzato A, De Ceulaer K, Cohen H, Tektonidou M, Andrade D on behalf of APS ACTION. APS ACTION Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk[abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10)#2189 – (ACR 2015)

• Zuily S, Andrade D, Erkan D, and Tektonidou M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Impact of SLE in the Clinical Phenotype of aPL-positive patients. Annals of Rheumatic Disease 2016;FRI0314 – (EULAR 2016)

• Sciascia S , Willis R , Pengo V, Krilis S , Andrande D, Erkan D, Bertolaccini M. on behalf of APS ACTION. APS ACTION Clinical Database & Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results. Lupus 2016;25 (Supp 1S):23 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Efthymiou M , Mackie I , Lane P , Pengo V, Andrade D, Willis R, Krilis S , Erkan D, Cohen H on behalf of APS ACTION. APS ACTION Clinical Database & Repository Analysis: The Comparison of Real World and Core Laboratory Lupus Anticoagulant Results. Lupus 2016;25 (Supp 1S):23 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Yazici A , Unlu O , Chighizola C , Erkan D, Petri M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Frequency & Significance of IgA Anticardiolipin and Antib2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with/without Lupus. Lupus 2016;25 (Supp 1S):27 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Unlu O , Zuily S , Davis S, Andrade D , Erkan D, Tektonidou M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Impact of Systemic Lupus Erythematous on the Clinical Phenotype of Antiphospholipid Antibodypositive Patients. Lupus 2016;25 (Supp 1S):41 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Sciascia S , Ramires de Jesu´s G , Zuily S , Levy R, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Utility of Global Antiphospholipid Syndrome Score (GAPSS) as a Tool to Assess Thrombosis Risk in Patients Presenting with Pure Obstetric APS. Lupus 2016;25 (Supp 1S):51 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Zuily S, Clerc-Urmes I, Chighizola C , Baumann C, Wahl D, Meroni P, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis for the Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients With a History of Pregnancy. Lupus 2016;25 (Supp 1S):61 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Ramires de Jesus G , Sciascia S, Zuily S, Erkan D, Levy R on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Factors Associated with First Thrombosis in Patients Presenting with Pure Obstetric APS. Lupus 2016;25 (Supp 1S):61 –(15th International Congress on Antiphospholipid Antibodies 2016)

• Unlu O, Branch W, Fortin P, Gerosa M, Pons-Estel G, Tektonidou M, Ugarte A, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: First and Recurrent Thrombosis Risk After 720 Patient-Years of Follow-Up. Lupus2016;25 (Supp 1S):73 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Zuily S, Clerc-Urmes I, Wahl, Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and Repository Cluster Analysis for Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Patients. Lupus 2016;25 (Supp1S):74 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Zuily S, Clerc-Urmes I, Baumann C, Erkan D, Tektonidou M on behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis for the Associations Among ‘‘Non-Criteria’’ Antiphospholipid Antibody Manifestations. Lupus 2016;25 (Supp 1S):75 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Unlu O, Erkan D, Tektonidou M and on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients. Lupus 2016;25 (Supp 1S):75 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Ugolini-Lopes M, Rosa R, Nascimento I, R de Jesus G, Levy R, Erkan D, Andrade D onBehalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Primary Antiphospholipid Syndrome in Brazil versus Other Regions of the World. Lupus 2016;25 (Supp 1S):76 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Erkan D, Sciascia S, Unlu O, Belmont M, Branch W, Cuadrado M, Gonzalez E, Knight J, Uthman I, Willis R, Zhang Z, Zuily S, Wahl D, Tektonidou M and on Behalf of APS ACTION. A Multicenter Randomized Controlled Trial of Hydroxychloroquine in Primary Thrombosis Prophylaxis of Persistently Antiphospholipid Antibody-positive Patientswithout Systemic Autoimmune Diseases. Lupus 2016;25 (Supp 1S): 88 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Rodriguez-Pinto I , Pons-Estel G , Andreoli L, Tincani A, Espinosa G, Cervera R , Erkan D on behalf of APS ACTION. APS ACTION Clinical Database and RepositoryAnalysis: “Real Life” Hydroxychloroquine use in Primary Antiphospholipid Syndrome.Lupus 2016;25 (Supp 1S): 90 – (15th International Congress on Antiphospholipid Antibodies 2016)

• Unlu O, Cohen H, Cuadrado M, Fortin P, R de Jesus G, Gerosa M, Knight J, Pengo V, Clinical Database and Repository Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients. Lupus 2016;25 (Supp 1S): 93 –  (15th International Congress on Antiphospholipid Antibodies 2016)

• Unlu O, Cohen H, Cuadrado MJ, Fortin PR, Ramires de Jesus G, Gerosa M, Knight JK, Pengo V, Petri M, Rodriguez-Almaraz E, Zuily S, Erkan D on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients. Arthritis Rheumatol 2016; 68 (suppl10) #1064 – (ACR 2016)

• Unlu O, Erkan D, Tektonidou M on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients. Arthritis Rheumatol. 2016; 68(suppl 10) #1072 – (ACR 2016)

• Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Erkan D, Bertolaccini ML on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results. Arthritis Rheumatol. 2016; 68 (suppl 10). #1073 – (ACR 2016)

• Yazici A, Unlu O, Chighizola CB, Erkan D, Petri M, on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: The Frequency and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with and without Lupus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10) #1964 – (ACR 2016)

• Unlu O, Branch WD, Fortin PR, Gerosa M, Pons-Estel GJ, Tektonidou M, Ugarte A, Erkan D Clinical Database and Repository Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up [abstract]. Arthritis Rheumatol. 2016; 68(suppl 10) #1965 (ACR 2016)

• Jackson WG, Oromendia C, Unlu O, Erkan D, and De Sancho MT. Recurrent Thrombosis in Patients with Antiphospholipid Antibodies and Arterial Thrombosis Treated with Antiplatelets and/or Anticoagulant Therapy (ASH 2017)

• Efthymiou M, Mackie I, Lane P, Pengo V, Andrade D, Willis R, Krilis S, Erkan D, Cohen H on Behalf of APS ACTION. APS ACTION: Comparison of Real World and Core Laboratory Lupus Anticoagulant Results. Res Pract Thromb Haemost. 2017;1(Suppl. 1):1104. (ISTH 2017)

• Unlu O, Andrade D, Banzato A, Branch DW, Fortin P, Gerosa M, Levy RA, Lopes M, Petri M, Rodriguez I, Tektonidou M, Ugarte A, Willis R, Erkan D on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up. Arthritis Rheumatol. 2017; 69 (suppl 10) (ACR 2017)

• Sevim E, Andrade D, Banzato A, Branch DW, Cervera R, Ramires de Jesus G, Knight JS, Meroni PL, Tektonidou M, Tincani A, Ugarte A, Zhuli Z, Erkan D on Behalf of APS ACTION. APS ACTION Clinical Database and Repository Analysis: Pregnancy Outcomes Since Inception. Arthritis Rheumatol. 2017; 69 (suppl 10).  (ACR 2017)

• Sevim E, Andrade D, Banzato A, Tektonidou M, Ugarte A, Chighizola CB, Ji L, Branch D, Ramires de Jesus G, Andreoli L, Petri M, Cervera R, Knight JS, Atsumi T, Erkan D on Behalf of APS ACTION. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract].Arthritis Rheumatol. 2018; 70 (suppl 10) (ACR 2018)

• Sevim E, Zisa DF, Andrade D, Pengo V, Tektonidou M, Ugarte A, Gerosa M, Ji L, Efthymiou M, Ramires de Jesus G, Branch D, Nalli C, Sciascia S, Belmont HM, Fortin PR, Petri M, Rodriguez-Almaraz E, Quintana R, Knight JS, Willis R, Atsumi T, Bertolaccini ML, Erkan D, Barbhaiya M on Behalf of APS ACTION. Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10) (ACR 2018)

• Sevim E, Unlu O, Andrade D, Banzato A, Tektonidou M, Ugarte A, Gerosa M, Cohen H, Branch D, Ramires de Jesus G, Tincani A, Fortin PR, Petri M, Rodriguez I, Knight JS, Atsumi T, Willis R, Roubey R, Erkan D on Behalf of APS ACTION. First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10) (ACR 2018)

• Efthymiou M; Mackie I; Lane P; Andrade D; Wills R; Krilis S; Erkan D; Sciascia S; Bison E; Vendramini MBG; Romay-Penabad Z; Qi M; Bertolaccini ML; Pengo V; Cohen H on behalf of APS ACTION. Standardization and Reliability of Lupus Anticoagulant Tests: Comparison of Real World and Core Laboratory Results from the APS ACTION Analysis. RPTH; PB0476. (ISTH 2019)

• Sevim E, Zisa D, Andrade D, Pengo V, Sciascia S, Tektonidou M, Ugarte A, Gerosa M, Belmont H, Lopez Pedrera R, Ji L, Fortin P, Efthymiou M, De Jesus G, Branch D, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight J, Atsumi T, Willis R, Bertolaccini M, Cohen H, Roubey R, Erkan D, Barbhaiya M on Behalf of APS ACTION. The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the APS ACTION Clinical Database and Repository (“Registry”) – (16th International Congress on Antiphospholipid Antibodies 2019)

• Sevim E, de Jesus GR, Ji L, Ugarte A, Pengo V, Cervera R, Tincani A, Tektonidou MG, Atsumi T, Knight J, Petri M, Branch W, and Erkan D on Behalf of APS ACTION. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from APS ACTION Clinical Database and Repository (“Registry”) – (16th International Congress on Antiphospholipid Antibodies 2019)

• Efthymiou M, Mackie I, Lane P, Andrade D, Wills R, Krillis S, Erkan D, Sciascia S, Bertolaccini M, Pengo V, Cohen H on behalf of APS ACTION. Comparison of local and Core Laboratory Lupus Anticoagulant Results from the Antiphospholipid Syndrome ACTION Clinical Database/Repository – (16th International Congress on Antiphospholipid Antibodies 2019)

• Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, Sciascia S, Tektonidou M, Ugarte A, Chighizola C, Belmont H, Pérez Sánchez L, Ji L, Fortin P, Efthymiou M, De Jesus G, Branch D, Nalli C, Petri M, Cervera R, Rodriguez E, Knight J, Atsumi T, Willis R, Bertolaccini M, Cohen H, Rand J, Erkan D, Of APS ACTION O. Antiphospholipid Antibody Profile Stability over Time: Prospective Results from APS ACTION Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol.2019; 71 (suppl 10) (ACR2019)

• Taghavi M, Barbhaiya M, Tektonidou M, Fortin P, Andrade D, Knight J, Artim-Esen B, Atsumi T, Cohen H, Ji L, Sciascia S, Seshan S, Erkan D, APS ACTION. Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the APS ACTION Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol.2019; 71 (suppl 10) (ACR2019)

• Sevim E, Zisa D, Andrade D, Pengo V, Sciascia S, Tektonidou M, Ugarte A, Gerosa M, Belmont H, Lopez Pedrera R, Ji L, Fortin P, Efthymiou M, De Jesus G, Branch D, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight J, Atsumi T, Willis R, Bertolaccini M, Cohen H, Roubey R, Erkan D, Barbhaiya M, APS ACTION o. The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the APS ACTION Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol.2019; 71 (suppl 10) (ACR 2019)

• Ahmadzadeh Y, Andrade D, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont H, Gerosa M, Fortin P, Aguirre M, Ji L, Atsumi T, Cohen H, de Jesus G, Branch D, Tincani A, Kello N, Petri M, Rodriguez-Almaraz E, Ríos-Garcés R, Zuo Y, Artim-Esen B, Willis R, Bertolaccini M, Roubey R, Erkan D, APS ACTION. First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ( [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10) (ACR 2021)

• Erton Z, Sevim E, de Jesus G, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, Fortin P, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou M, Aguirre M, Branch D, Erkan D, APS ACTION. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract] (ACR 2021)

• Balbi G, Ahmadzadeh Y, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont H, Gerosa M, Fortin P, lopez-pedrera C, Ji L, Atsumi T, Cohen H, de Jesus G, Branch D, Nalli C, Kello N, Petri M, Rodriguez-Almaraz E, Barilaro G, Knight J, Artim-Esen B, Willis R, Bertolaccini M, Roubey R, Erkan D, De Andrade D, APS ACTION. Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10)  (ACR 2021)

• Erton Z, Karp- Leaf R, Andrade D, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont H, Gerosa M, Fortin P, lopez-pedrera C, Ji L, Atsumi T, Cohen H, de Jesus G, Branch D, Nalli C, Kello N, Petri M, Rodriguez-Almaraz E, Cervera R, Knight J, Artim-Esen B, Willis R, Bertolaccini M, Roubey R, Erkan D, APS ACTION. Immunosuppression Use in Primary Antiphospholipid Antibody Positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10) (ACR 2021)

• Chighizola C, Pregnolato F, De Andrade D, Tektonidou M, Pengo V, Ugarte A, Belmont H, Fortin P, Atsumi T, Efthymiou, M, de Jesus G, Branch D, Nalli C, Petri M, Rodriguez-Almaraz E, Cervera R, Zuo Y, Willis R, Bison E, Mackie I, Cohen H, Roubey R, Erkan D, Bertolaccini M. Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10) (ACR 2021)

• Gkrouzman E, Andrade D, Tektonidou M, Pengo V, Ugarte A, Belmont H, Chighizola C, Fortin P, Atsumi T, Efthymiou, M, de Jesus G, Branch D, Andreoli L, Petri M, Rodriguez-Almaraz E, Cervera R, Knight J, Gonzalez E, Bison E, Mackie I, Cohen H, Bertolaccini M, Erkan D, Roubey R, APS ACTION o. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10) (ACR 2021)

• Erton Zb, Leaf R, De Andrade D, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont M, Gerosa M, Fortin Pr, Aguirre Zamorano Ma, Atsumi T, Zhang Z, Cohen H, De Jesus G, Kello N, Branch W, Clarke Ae, Wahl D, Andreoli L, Rodríguez Almaraz E, Petri M, Cervera R, Zuo Y, Artim Esen B, Willis R, Pons-Estel G, Bertolaccini Ml, Roubey R, Erkan D, On Behalf Of Aps Action. Immunosuppression In Primary Antiphospholipid Antibody-Positive Patients: Descriptive Analysis Of The Aps Action Registry. Argentine Journal Of Rheumatology. Supplement 17th International Congress On Antiphospholipid Antibodies, 2022;33(2):12-13.

• Zuo Y, Navaz S, Tsodikov A, Kmetova K, Hoy C, S Yalavarthi S, De Andrade D, Tektonidou M, Sciascia S, Pengo V, Ruiz-Irastorza G, Belmont M, Gerosa M, Fortin Pr, De Jesus G, Branch W, Andreoli L, Rodríguez E, Petri M, Cervera R, Willis R, Erkan D, Knight J, On Behalf Of Aps Action. Anti-Net Antibodies In Antiphospholipid Antibody-Positive Patients: Results From The Aps Alliance For Clinical Trials And International Networking (Aps Action) Clinical Database And Repository (“Registry”). Argentine Journal Of Rheumatology. Supplement 17th International Congress On Antiphospholipid Antibodies, 2022;33(2):15.

• Cecchi I, Radin M, Foddai S, Bertolaccini Ml, De Adrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, Belmont Mh, Gerosa M, Fortin Pr, Lopez- Pedrera C, Zhang Z, Atsumi T, De Jesus G, Cohen H, Kello N, Branch W, Wahl D, Andreoli L, Rodriguez E, Petri M, Barber Mrw, Cervera R, Knight J, Artim-Esen B, Willis R, Pons-Estel G, Erkan D, Sciascia S, On Behalf Of Aps Action. Clinical And Serological Characteristics Of Ana-Positive Versus Ana-Negative Antiphospholipid Antibody-Positive Patients Without Other Systemic Autoimmune Diseases: Results From The Aps Action Clinical Database And Repository. Argentine Journal Of Rheumatology. Supplement 17th International Congress On Antiphospholipid Antibodies, 2022;33(2):100-101.

• Foddai Sg, Cecchi I, Radin M, Bertolaccini Ml, De Adrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, Belmont Mh, Gerosa M, Fortin Pr, Lopez- Pedrera C, Zhang Z, Atsumi T, De Jesus G, Efthymiou M, Kello N, Branch W, Wahl D, Andreoli L, Rodriguez E, Petri M, Clarke A, Cervera R, Knight J, Artim-Esen B, Willis R, Pons-Estel G, Erkan D, Sciascia S, On Behalf Of Aps Action. Clinical Characteristics Of “Single” Antiphospholipid Antibody (Apl) Positive Thrombotic Aps Patients: Retrospective Results From The Aps Action Clinical Database And Repository (“Registry”). Argentine Journal Of Rheumatology. Supplement 17th International Congress On Antiphospholipid Antibodies, 2022;33(2):106-107.

• Chighizola Cb, Pregnolato F, De Adrade D, Tektonidou M, Sciascia S, Pengo V, Ugarte A, Belmont Mh, Gerosa M, Fortin Pr, Lopez- Pedrera C, Atsumi T, De Jesus G, Zhang Z, Branch W, Kello N, Andreoli, Wahl D, Petri M, Rodriguez Almaraz E, Cervera R, Pons-Estel G, Willis R, Knight J, Barber M, Artim-Esen B Cohen H, Erkan D, Bertolaccini Ml, On Behalf Of Aps Action. Hydroxychloroquine Affects The Fluctuation Of Anti-Domain 1 Antibodies Over Time In Patients With Persistently Positive Antiphospholipid Antibodies: Results From The Aps Action Clinical Database And Repository (“Registry”). Argentine Journal Of Rheumatology. Supplement 17th International Congress On Antiphospholipid Antibodies, 2022;33(2):118.

• Chighizola, F. Pregnolato, D. Andrade, M. Tektonidou, S. Sciascia, V. Pengo, A. Ugarte, H. M. Belmont, M. Gerosa, P. Fortin, C. Lopez-Pedrera, Z. Zhang, T. Atsumi, G. De Jesùs, N. Kello, D. W. Branch, L. Andreoli, D. Wahl, M. A. Petri, E. Rodríguez Almaraz, R. Cervera, G. Pons Estel, J. Knight, R. Willis, M. Barber, B. Artim Esen, M. Efthymiou, D. Erkan, M. L. Bertolaccini, on behalf of APS ACTION. Hydroxychloroquine Reduces The Titers Of Anti-Domain 1 Antibodies Over Time In Patients With Persistently Positive Antiphospholipid Antibodies: Results From The Aps Action Clinical Database And Repository (“Registry”). Annals Rheum Dis 2022;81(supp1):484 (abstract) (EULAR 2022)

• Zuo Y, Navaz S, Tsodikov A, Kmetova K, Hoy C, Yalavarthi S, Castro Oliveira de Andrade D, Tektonidou M, Sciascia S, Pengo V, Ruiz-Irastorza G, Belmont H, Gerosa M, Fortin P, de Jesús G, Branch D, Andreoli L, Rodriguez Almaraz E, Petri M, Cervera R, Willis R, Erkan D, Knight J. Anti-NET Antibodies in Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol.2022; 74 (suppl 9). (ACR 2022 PODIUM PRESENTATION)

• Yelnik C, Erton Z, Drumez E, Cheildze D, Castro Oliveira de Andrade D, Clarke A, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont H, Aguirre M, fortin P, gerosa m, Signorelli F, Atsumi T, Zhang Z, Cohen H, Branch D, Wahl D, Andreoli L, Rodriguez Almaraz E, Petri M, Cervera R, Zuo Y, Artim-Esen B, Pons-Estel G, Willis R, Bertolaccini M, Roubey R, Erkan D, On Behalf Of APS ACTION. Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol.2022; 74 (suppl 9). (ACR 2022 – PODIUM PRESENTATION).

• Erton Z, K.Leaf R, Castro Oliveira de Andrade D, Barber M, Tektonidou M, Pengo V, Sciascia S, Ugarte A, Belmont H, López-Pedrera C, Fortin P, gerosa m, de Jesús G, Atsumi T, ZHANG Z, Cohen H, Branch D, WAHL D, Andreoli L, Rodriguez Almaraz E, Petri M, Cervera R, Zuo Y, Artim-Esen B, , Willis R, Bertolaccini M, Roubey R, Erkan D, On Behalf Of APS ACTION. Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol.2022; 74 (suppl 9) (ACR 2022).

• Cecchi I, Radin M, Foddai S, Bertolaccini M, De Andrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, Belmont H, Gerosa M, Fortin P, Lopez-Pedrera C, Zhang Z, Atsumi T, de Jesus G, Cohen H, Kello N, Branch W, Wahl D, Andreoli L, Rodriguez E, Petri M, Barber M, Cervera R, Knight J, Artim-Esen B, Willis R, Pons-Estel G, Erkan D, Sciascia S. ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository [abstract]. Arthritis Rheumatol.2022; 74 (suppl 9) (ACR 2022).

• Foddai S, Cecchi I, Radin M, De Andrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, Belmont H, Gerosa M, Fortin P, Lopez-Pedrera R, Zhang Z, Atsumi T, de Jesus G, Cohen H, Kello N, Branch W, Wahl D, Andreoli L, Rodriguez E, Petri M, Clarke A, Cervera R, Knight J, Artim-Esen B, Willis R, Pons-Estel G, Erkan D, Roccatello D, Sciascia S. Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry) [abstract]. Arthritis Rheumatol.2022; 74 (suppl 9) (ACR 2022).

• Butt A, Garcia-Milian R, Goshua G, Gu S, Hwa J, Chun H, Belmont H. M., Kello N., Branch D.W., Petri M., Knight J. S., Willis R., Bertolaccini M.L., Erkan D., Lee A.I., Sharda A., Pine A.B. Proteomic Profiling Of Different Antiphospholipid Antibody-Positive Phenotypes: Results From APS ACTION Registry. (European Hematology Association Annual Congress 2023)

• Thaler J, Ahmadzadeh Y, Andrade D, skeith l, Tektonidou M, Sciascia S, Pengo V, Pardos-Gea J, Ruiz-Irastorza G, Lopez-Pedrera C, Belmont H, Nina K, Fortin P, WAHL D, Gerosa M, De Jesús G, Zhang Z, Atsuma T, Efthymiou M, Branch D, Andreoli L, Rodriguez almaraz E, Petri M, Pazzola G, Cervera R, Artim Esen B, Shi H, Knight J, Pons-Estel G, Willis R, Duarte-Garcia A, Bertolaccini M, Cohen H, Erkan D, Of APS ACTION O. First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9) (ACR 2023 PODIUM PRESENTATION).

• Yelnik C, Chaturvedi S, Labreuche J, Pan X, Belmont H, Nina K, Fortin P, Branch D, Zuo Y, Willis R, Brodsky R, Salmon J, Bertolaccini M, Cohen H, Petri M, Erkan D, Of APS ACTION O. Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9) (ACR 2023 PODIUM PRESENTATION).

• Butt A, Garcia Milian R, Goshua G, Gu S, Chock E, Restrepo V, Hwa J, Chun H, Belmont H, Nina K, Branch D, Petri M, Knight J, Willis R, Bertolaccini M, Erkan D, lee A, Sharda A, Pine A. Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9) (ACR 2023 PODIUM PRESENTATION)

• Efthymiou M, Mackie I, Willis R, Pengo V, Andrade D, Bison E, Amengual O, Romay-Penabad Z, Fujieda Y, Bertolaccini M, Erkan D, Cohen H, Of APS ACTION O. Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9) (ACR 2023).

• Erton Z, Thaler J, Andrade D, Barber M, Tektonidou M, Sciascia S, Pengo V, Pardos-Gea J, Ruiz-Irastorza G, Lopez-Pedrera C, Belmont H, Nina K, Fortin P, Zuily S, Chighizola C, Signorelli F, Zhang Z, Atsuma T, Efthymiou M, Branch D, Nalli C, Rodriguez almaraz E, Petri M, Pazzola G, Cervera R, Artim Esen B, Shi H, Zuo Y, Quintana R, Willis R, Duarte-Garcia A, Bertolaccini M, Cohen H, Erkan D, Of APS ACTION O. Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9) (ACR 2023).

• Ahmadzadeh Y, Magder L, Ozdemir Z, Andrade D, Barber M, Tektonidou M, Sciascia S, Pengo V, Anunciación-Llunell A, Ruiz-Irastorza G, Aguirre M, Belmont M, Nina K, Fortin P, WAHL D, Gerosa M, De Jesús G, Zhang Z, Atsuma T, Efthymiou M, Branch D, Tincani A, Rodriguez almaraz E, Pazzola G, Cervera R, Artim Esen B, Shi H, Knight J, Pons-Estel G, Willis R, Duarte-Garcia A, Bertolaccini M, Cohen H, Petri M, Erkan D, Of APS ACTION O. Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry” [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9) (ACR 2023).

• Willis R, Tebo A, Skeith L, Kello N, Belmont H, Fortin P, Ramires de Jesús G, Branch D, Petri M, Knight J, Kose Cobanoglu R, Bertolaccini M, Cohen H, Roubey R, Erkan D, Andrade D. Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9) (ACR 2024).

• Vandevelde A, Meroni P, Cohen H, Andrade D, Amengual O, ATSUMI T, Tincani A, Belmont H, Borghi M, Branch D, Cervera R, Ramires de Jesús G, Fortin P, Gris J, Grossi C, Knight J, Moore G, Musiał J, Petri M, Rodriguez-Almaraz E, Paredes-Ruiz D, Roubey R, Tebo A, Tektonidou M, WAHL D, Zuily S, Willis R, Pengo V, Bertolaccini M, Erkan D, Devreese K. Efforts to Harmonize ELISA and Non-ELISA Anticardiolipin and Anti-β2-glycoprotein-I Levels Based on ISTH SSC LA/aPL and APS ACTION International Multicenter Cohorts [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9) (ACR 2024).

• Thaler J, Parides M, Andrade D, Paredes-Ruiz D, Tektonidou M, Pengo V, Sciascia S, Nalli C, Ramires de Jesús G, Fortin P, Efthymiou M, Belmont H, Petri M, Cervera R, Skeith L, ATSUMI T, Lopez-Pedrera C, Zuo Y, Branch D, Willis R, Kello N, Zhang Z, Rodriguez-Almaraz E, Artim Esen B, Pardos-Gea J, Pons-Estel G, Pazzola G, Shi H, Duarte-Garcia A, Barbhaiya M, Yelnik C, Meroni P, Roubey R, Bertolaccini M, Cohen H, Rand J, Erkan D. Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9) (ACR 2024 PODIUM PRESENTATION).

• Pine A, Pengo V, Sciascia S, Kello N, Lopez Pedrera R, Belmont H, Branch D, Andreoli L, Petri M, Cervera R, Knight J, Meroni P, Cohen H, Willis R, Bertolaccini M, Lee A, Erkan D, Sharda A. Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9) (ACR 2024).

• Yelnik C, Chaturvedi s, Labreuche J, Pan X, Belmont H, Kello N, Fortin P, Branch D, Zuo Y, Willis R, Brodsky R, Salmon J, Bertolaccini M, Cohen H, Petri M, Erkan D. Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9) (ACR 2024).

• Gkrouzman E, Clarke A, Tektonidou M, Pengo V, Sciascia S, Pardos-Gea J, Kello N, Paredes-Ruiz D, Aguirre-Zamorano M, Belmont H, Fortin P, Ramires de Jesús G, Atsumi T, Zhang Z, Efthymiou M, Branch D, Pazzola G, Andreoli L, Duarte-Garcia A, Rodriguez-Almaraz E, Petri M, Cervera R, Artim Esen B, Pons-Estel G, Shi H, Knight J, Willis R, Meroni P, Bertolaccini M, Cohen H, Roubey R, Andrade D, Erkan D. Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9) (ACR 2024).

• Kose Cobanoglu R, Willis R, Paredes-Ruiz D, Tektonidou M, Pengo V, Sciascia S, Nalli C, Signorelli F, Fortin P, Efthymiou M, Belmont H, Petri M, Cervera R, Barber M, ATSUMI T, Lopez-Pedrera C, Knight J, Branch D, Kello N, Ji L, Rodriguez-Almaraz E, Artim Esen B, Pardos Gea J, Quintana R, Pazzola G, Shi H, Duarte-Garcia A, Meroni P, Roubey R, Bertolaccini M, Cohen H, Andrade D, Erkan D. The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9) (ACR 2024 PODIUM PRESENTATION).